Cryoelectron Microscopy Structures of AdeB Illuminate Mechanisms of Simultaneous Binding and Exporting of Substrates

Christopher E. Morgan, Przemyslaw Glaza, Inga V. Leus, Anhthu Trinh, Chih-Chia Su, Meng Cui, Helen I. Zgurskaya, Edward W. Yu

Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma, USA
Department of Pharmaceutical Sciences, Northeastern University School of Pharmacy, Boston, Massachusetts, USA

Christopher E. Morgan and Przemyslaw Glaza contributed equally to this work. Author order was determined in order of seniority.

ABSTRACT  Acinetobacter baumannii is a Gram-negative pathogen that has emerged as one of the most highly antibiotic-resistant bacteria worldwide. Multidrug efflux within these highly drug-resistant strains and other opportunistic pathogens is a major cause of failure of drug-based treatments of infectious diseases. The best-characterized multidrug efflux system in A. baumannii is the prevalent Acinetobacter drug efflux B (AdeB) pump, which is a member of the resistance-nodulation-cell division (RND) superfamily. Here, we report six structures of the trimeric AdeB multidrug efflux pump in the presence of ethidium bromide using single-particle cryoelectron microscopy (cryo-EM). These structures allow us to directly observe various novel conformational states of the AdeB trimer, including the transmembrane region of trimeric AdeB can be associated with form a trimer assembly or dissociated into “dimer plus monomer” and “monomer plus monomer plus monomer” configurations. We also discover that a single AdeB protomer can simultaneously anchor a number of ethidium ligands and that different AdeB protomers can bind ethidium molecules simultaneously. Combined with molecular dynamics (MD) simulations, we reveal a drug transport mechanism that involves multiple multidrug-binding sites and various transient states of the AdeB membrane protein. Our data suggest that each AdeB protomer within the trimer binds and exports drugs independently.

IMPORTANCE  Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant Gram-negative pathogens. The prevalent AdeB multidrug efflux pump mediates resistance to a broad spectrum of clinically relevant antimicrobial agents. Here, we report six cryo-EM structures of the trimeric AdeB pump in the presence of ethidium bromide. We discover that a single AdeB protomer can simultaneously anchor a number of ligands, and different AdeB protomers can bind ethidium molecules simultaneously. The results indicate that each AdeB protomer within the trimer recognizes and extrudes drugs independently.

KEYWORDS  Acinetobacter baumannii, AdeB multidrug efflux pump, cryo-EM, multidrug resistance, structural biology

Acinetobacter baumannii is an opportunistic Gram-negative pathogen that has emerged as one of the most problematic and highly antibiotic-resistant bacteria in the world. This bacterial pathogen exhibits a high level of antimicrobial resistance (AMR) to a broad spectrum of agents (1, 2). To date, emerging carbapenem-resistant A. baumannii is listed in the highest AMR threat category by the CDC, with carbapenem
resistance now found in the majority of A. baumannii strains worldwide (3, 4). Correspondingly, the WHO also lists carbapenem-resistant A. baumannii as a first-priority pathogen for the research and development of new antibiotics (5). Unfortunately, there is an increasing trend of resistance to even the last-resort antibiotics, such as colistin and tigecycline (6–9). These resistant strains are essentially nonsusceptible to every FDA-approved antibiotic and, hence, are untreatable. Currently, there is no standard treatment regimen for Acinetobacter infections, and empirical therapy is not always reliable. In addition, A. baumannii can survive for prolonged periods in clinical settings, potentiating its spread as a nosocomial pathogen affecting our most vulnerable patients (10, 11).

Multidrug efflux is considered one of the major causes of the failure of drug-based treatments of infectious diseases (12). In A. baumannii, the best-characterized multidrug efflux system is the prevalent Acinetobacter drug efflux ABC (AdeABC) trimeric system (13). This efflux system is capable of mediating resistance to a broad spectrum of clinically relevant antimicrobial agents, such as aminoglycosides, tetracyclines, macrolides, β-lactams, fluoroquinolones, chloramphenicol, and trimethoprim (1, 13–20). The AdeABC locus consists of three tandemly linked genes encoding the AdeA periplasmic membrane fusion protein, the AdeB multidrug efflux pump, which is an inner membrane protein belonging to the hydrophobe-amphiphile efflux resistance-nodulation-cell division (HAE-RND) family of efflux transporters, and the AdeC outer membrane channel protein (13, 21). It should be noted that not all A. baumannii strains carry the adeC gene. However, it has been demonstrated that the presence of adeC can elevate the levels of resistance to several antibiotics (22).

To understand the mechanisms of substrate recognition and extrusion of the A. baumannii AdeB multidrug efflux pump, here, we define cryoelectron microscopy (cryo-EM) structures of this membrane protein embedded in lipidic nanodiscs in the presence of ethidium bromide (Et). The approach of using lipidic nanodiscs is beneficial to structural determination of this membrane protein, as we can avoid the harsh detergent environment during the process of single-particle imaging. In addition, cryo-EM has the ability to study various conformational states of biomacromolecules within a single sample (23, 24), accelerating the elucidation of the conformations of various transient states that the multidrug efflux pump must go through during the drug transport cycle. Recently, we developed a novel iterative methodology, termed “build and retrieve” (BaR), to process heterogeneous sample data sets for high-resolution structural determination (25). It is a powerful technique that enables us to sort and separate cryo-EM images into various proteins and/or different conformational classes of the same protein. With the cryo-EM approach, we are able to observe detailed structural information of various transient states that are crucial for understanding the mechanisms of multidrug recognition and extrusion of the AdeB pump. Here, we present six cryo-EM structures of the trimeric A. baumannii AdeB multidrug efflux pump either alone or bound with Et molecules. Interestingly, these structural data allow us to directly observe two new phenomena, that a single AdeB protomer can simultaneously accommodate multiple Et ligands and that different AdeB protomers within the trimer are capable of binding Et simultaneously. Additionally, we notice that the transmembrane region of trimeric AdeB can switch its oligomerization from “trimer” to “dimer plus monomer” and “monomer plus monomer plus monomer” configurations. We also investigate the functional dynamics of this transporter using molecular dynamics (MD) and target MD (TMD) simulations. Combined, our data provide a detailed pathway for substrate transport via the AdeB membrane protein.

RESULTS

Structural determination of the AdeB multidrug efflux pump. To confirm that substrates bind A. baumannii AdeB with sufficient affinity to visualize via structural analysis, we first purified the full-length multidrug efflux pump and used the technique of fluorescence polarization to quantify the interactions of purified AdeB with ethidium bromide (Et) and rhodamine 6G (R6G). The titration experiments indicate that AdeB
specifically binds these two substrates in the micromolar range. The measured dissociation constant \( (K_d) \) values for Et and R6G are 2.5 ± 0.1 \( \mu \)M and 3.1 ± 0.1 \( \mu \)M, respectively (see Fig. S1 in the supplemental material). These \( K_d \)s are similar to those measured for the \textit{Escherichia coli} AcrB multidrug efflux pumps (26) using the same technique.

\textit{A. baumannii} encodes seven RND-type efflux pumps (17), with AdeABC and AdeUK being responsible for resistance to most clinically relevant antibiotics. However, the expression level of AdeABC is the highest among these tripartite efflux pumps (27). We used an \textit{A. baumannii} \( \Delta \text{adeABC} \Delta \text{adeFGH} \Delta \text{adeIJK} \) (\( \text{AbD3} \)) triple-knockout strain (28), which harbors deletions in the chromosomal \textit{adeABC}, \textit{adeFGH}, and \textit{adeIJK} genes, from the clinical MDR isolate AYE. We found that the MICs of Et in the efflux-deficient \( \text{AbD3} \) cells were 4 to 8 mg/liter, but the MIC was increased to 32 to 64 mg/liter when these \( \text{AbD3} \) cells were complemented with the plasmid-borne AdeABC pump. Further, Et readily accumulated in efflux-deficient hyperporinated \( \text{AbD3-Pore} \) cells (28), as seen from the increase in Et fluorescence of these cells in concentration- and time-dependent manners (Fig. S1). In contrast, no significant time-dependent accumulation of Et was observed in the \textit{AdeABC-overproducing AbD3-Pore(pAdeABC)} cells (28) (Fig. S1). Combined with fluorescence polarization, these data strongly indicate that Et is a substantive substrate of the AdeB multidrug efflux pump.

We then reconstituted the purified AdeB membrane protein into lipidic nanodiscs. We incubated 2 \( \mu \)M AdeB-nanodisc sample with 20 \( \mu \)M Et for 2 h and collected single-particle cryo-electron microscopy (cryo-EM) images of the AdeB-Et complex. Cryo-EM detects single-particle images at random orientations in a solution state where the protein molecules are free to change conformation to accommodate substrate binding and transport. Therefore, we believe that these cryo-EM images should contain invaluable information regarding different intermediates the pump must adopt within the transport cycle. Extensive classification of the single-particle images indicated that there were six distinct populations of AdeB with different conformations coexisting in the single nanodisc sample (Fig. S2). Several iterative rounds of classifications allowed us to sort the images based on these six distinct conformations. Surprisingly, three of these structures depicted that the trimeric AdeB pump does not contain any bound ligands. For the other three AdeB structures, it was observed that one of the AdeB protomers within the trimer possesses two or three bound Et molecules. Interestingly, one of these three AdeB-Et complex structures showed that two independent AdeB protomers within the trimer can simultaneously anchor Et ligands.

\textbf{Structures of apo-AdeB.} Three distinct conformations of apo-AdeB (AdeB-I, AdeB-II, and AdeB-III) were captured in our cryo-EM data (Fig. 1, Fig. S2 and S3, and Table S1). All of these structures depict that AdeB adopts the fold of a typical HAE-RND-type protein and forms a homotrimer, with its 3-fold symmetrical axis positioned perpendicular to the membrane surface. Each subunit of AdeB contains 12 transmembrane helices (TM1 to TM12) and six periplasmic subdomains (PN1, PN2, PC1, PC2, DN, and DC). The assignments of the AdeB protomers are shown in Fig. S4 and Table S2.

(i) \textbf{Structure of AdeB-I.} In the structure of AdeB-I, the three AdeB protomers are identical in conformation, displaying the “extrusion” state of the pump (Fig. 1, Fig. S3, and Table S1). The periplasmic cleft created by subdomains PC1 and PC2 is closed. An extrusion channel is found in each AdeB protomer (Fig. 1). It is interesting that the three AdeB molecules tightly interact with each other, both in the transmembrane and the periplasmic regions, to form a trimer in this state. Within the transmembrane domain, six phosphatidylethanolamine (PE) molecules were observed to bind at the outer leaflet region of the trimeric AdeB pump (Fig. S5). Each AdeB protomer forms two distinct PE lipid-binding sites. One of these two binding sites is located at the interior surface of the large central cavity of the trimeric AdeB efflux pump, with each individual AdeB protomer solely responsible for its binding. The other lipid binding site is found within the protomer-protomer interface, where two AdeB protomers interact with each other within their transmembrane regions to anchor this bound PE molecule. It
appears that the TM-associated PE molecule may help promote these protomer-proto-
mer interactions within the subunit interface.

**(ii) Structure of AdeB-II.** Like AdeB-I, the three AdeB protomers of the second apo-
AdeB structure, designated AdeB-II, present an extrusion conformation, where the three periplasmic clefts of the AdeB trimer are closed and a channel for extrusion is
found in each protomer (Fig. 1, Fig. S3, and Table S1). However, in the AdeB-II structure,
it is observed that the organization of the AdeB trimer is packed in a way that can be
interpreted as a dimer plus monomer configuration at the transmembrane domain (Fig. 1). The region that maintains the assembly of the pump in the trimeric oligomeri-
zation state is the periplasmic domain, where the long-arm feature formed by subdo-
main DN strongly coordinates with the hook-like structural feature of subdomain DC of
the neighboring AdeB subunit to secure intersubunit interactions within the trimer.
This region also contributes to form a hinge so that the transmembrane domain of
each protomer is capable of shifting toward and away from each other. Within the two
protomers interacting with each other at the transmembrane region, we observed
three bound PE lipids. One of these lipids is located at the interface between the two
AdeB protomers. The other two lipid molecules are found to bind by individual proto-
mers (Fig. S5). No lipid is observed to associate with the third AdeB protomer.
(iii) Structure of AdeB-III. Strikingly, for the AdeB-III structure, the three AdeB protomers largely organize in a monomer plus monomer plus monomer configuration in the transmembrane region (Fig. 1, Fig. S3, and Table S1). In this conformational state, the three transmembrane domains of the AdeB trimer are significantly distant from each other and do not seem to participate in intersubunit interactions, although each AdeB protomer still presents an extrusion conformation of the pump with an extrusion channel creating at the periplasmic domain (Fig. 1). Interestingly, no noticeable lipid ligand was bound by these three AdeB protomers (Fig. S5). Like the dimer plus monomer configuration of the AdeB-II structure, the three AdeB protomers of AdeB-III specifically contact each other via the periplasmic domains, where DN of one AdeB subunit interacts with DC of another subunit to maintain trimeric oligomerization of the pump.

Previously, a cryo-EM structure of the AcrAB-ToIC (29) and X-ray structure of the CusAB (30) efflux complexes indicated that the adaptor proteins AcrA and CusB specifically interact with the efflux pumps AcrB and CusA, respectively. In particular, the 2.9-Å-resolution structure of CusAB depicted that domains 1 and 2 (corresponding to the membrane-proximal and β-barrel domains) of the CusB adaptor distinctly contacts the periplasmic subdomains PN2, PC1, and PC2 of the CusA pump via charge-charge, charge-dipole, and dipole-dipole interactions (30). Isothermal titration calorimetry further suggested that the binding affinity between CusA and CusB is 5.1 μM with stoichiometry of a 1:2 CusA-to-CusB molar ratio (30). We suspect that the switch in conformation of the trimeric AdeB pump from trimer to dimer plus monomer and monomer plus monomer plus monomer can alter the interactions between the AdeB pump and AdeA adaptor at the protein-protein interface, in turn facilitating the transport of substrates across the periplasmic space of A. baumannii.

Structures of AdeB-Et. In addition to the three apo-AdeB structures, we also observed three distinct structures of AdeB bound with Et in our cryo-EM sample. These three different AdeB-Et complex structures were labeled as AdeB-Et-I, AdeB-Et-II, and AdeB-Et-III (Fig. S2, Fig. S6, and Table S1). Interestingly, the cryo-EM data indicate that all of these Et-bound structures present asymmetric trimers, where two or three protomers within each trimer are unique and display different conformational states.

(i) Structure of AdeB-Et-I. Surprisingly, the structure of AdeB-Et-I depicts that one of the AdeB protomers prefers a transient state with its periplasmic cleft open, whereas the periplasmic clefts of the other two protomers remain closed. These two protomers with the periplasmic cleft closed represent the extrusion conformation, as each protomer possesses an extrusion channel at the periplasmic domain (Fig. 2, Fig. S6, and Table S1). The conformation of the AdeB protomer with the open cleft presents the “binding” state of the pump. Within the binding protomer, an elongated channel allows for the interior of the periplasmic domain to be exposed to solvent. Unexpectedly, three extra densities were found in three distinct locations inside this open cleft. The shape of each density is compatible with Et, indicating that three Et molecules are simultaneously bound by this binding protomer. The three bound Et molecules appear to line the elongated channel formed by the protomer, depicting a path for drug transport. The first bound Et is situated at the entrance of the periplasmic cleft, where the entrance residues M656, V658, M706, W708, and I821 are responsible for providing hydrophobic and aromatic interactions to anchor-bound Et (Fig. 2). It should be noted that the corresponding AdeB residues M656, V658, and W708 are F664, F666, and R717 in the AcrB pump. These AcrB residues have been shown to be important for drug recognition (31–33). Interestingly, the gate loop (G-loop) is observed to swing toward the periplasmic entrance in this conformational state, enabling the G-loop residue F612 to come closer to bound Et (within 4.5 Å), forming an aromatic interaction to further stabilize Et binding. In AcrB, the G-loop phenylalanine is F617. Molecular dynamics simulations suggested that this AcrB F617 residue is important for substrate binding and extrusion (32).

The second Et molecule is bound at the same horizontal level compared with that of the first bound Et. This bound Et is located at the distal drug-binding site approximately 20 Å above the membrane surface. Within 4.5 Å of this bound Et, residues F136, L139, F178, A288, P326, Y327, W568, M570, T605, I607, F623, and T625 are responsible
for securing the binding of this bound Et (Fig. 2). The AdeB F178 residue corresponds to F178 in AcrB. This AcrB residue has been found to be involved in minocycline binding (34).

The third bound Et is observed to line up right above the second bound Et with respect to the membrane surface. Of note, the third Et is observed to entangle in the hydrophobic patch of the distal binding site. We designated this site a hydrophobic patch drug-binding site. Residues F178, F277, I279, I607, and W610 are engaged in anchoring this Et (Fig. 2). The corresponding hydrophobic patch residues in AcrB, including the AcrB residues F178, I277, V612, and F615, have been found to have the greatest impact on drug binding (32). Interestingly, the second bound Et in the distal drug-binding site is also within 4.5 Å and performs an aromatic interaction with the third bound Et at the hydrophobic patch site to secure the binding.

(ii) Structure of AdeB-Et-II. Similar to AdeB-Et-I, the structure of AdeB-Et-II indicates that the periplasmic cleft of one of the protomers is open and the clefts of the other two protomers are in closed conformation. A detailed inspection reveals that the conformational states of these three AdeB protomers within the AdeB-Et-II complex
resemble the crystal structure of the *Campylobacter jejuni* CmeB multidrug efflux pump (35), where the three CmeB protomers present the resting, extrusion, and binding conformations (Fig. 3, Fig. S6, and Table S1). Like the CmeB structure, no channel was found in the AdeB resting conformer. As expected, an extrusion channel was observed in the AdeB extrusion protomer, and an elongated channel that leads through the opening of the periplasmic cleft was identified in the AdeB binding protomer (Fig. 3, Fig. S6, and Table S1).

Within the binding protomer of AdeB, the cryo-EM images depict two extra densities corresponding to two bound Et molecules that were found at the entrance and distal drug-binding sites, respectively. However, there were no noticeable extra densities in the drug-binding sites of the resting and extrusion protomers. The first bound Et is anchored in a way very similar to that found in the entrance drug-binding site of AdeB-Et-I. The entrance binding site residues S572, M656, V658, M706, W708, and N709 of AdeB-Et-II attach this Et at the periplasmic entrance of AdeB-Et-II. The G-loop
residues F612 and S613 also contribute to this binding (Fig. 3). The second bound Et is found within the distal drug-binding site of AdeB-Et-II, where F136, L139, F178, I279, A288, P326, Y327, W568, T605, I607, T625, and F623 are responsible for the binding (Fig. 3). Interestingly, both Et molecules are bound approximately 2 Å above that of their corresponding Et found in AdeB-Et-I with respect to the membrane surface.

(iii) Structure of AdeB-Et-III. The trimeric AdeB-Et-III structure also exhibits an asymmetric conformation, with three distinct conformers in the trimer (Fig. 4, Fig. S6, and Table S1). It is clear that one AdeB protomer presents the binding state and a second AdeB protomer depicts the extrusion form of the pump. The third AdeB protomer displays a conformation that is more or less in good agreement with the “access” conformation of AcrB (34) and MtrD (36). Unexpectedly, a bound Et ligand was found within the entrance drug-binding site of this protomer. Therefore, we labeled this conformer the “access*” form of AdeB. The structure of AdeB-Et-III is distinct from all known structures of the RND-type efflux pumps in that two independent AdeB
protomers within the trimer are found to be occupied by substrates. This structural information strongly indicates that each AdeB protomer within the trimer can independently bind and export substrates. All of these different conformations most likely represent various intermediates that the AdeB pump must go through during the transport cycle to extrude drugs from bacterial cells.

In the binding conformer of AdeB-Et-III, there are two Et molecules occupying the periplasmic cleft. One Et molecule is found to bind at the entrance site, where residues F612, M656, V658, T668, E710, and I821 are responsible for anchoring this ligand (Fig. 4). The second Et molecule is observed to bind at the deep distal-binding pocket, with F136, L139, F178, I279, A288, Y327, W568, T605, I607, F623, and T625 participating in securing Et binding (Fig. 4). Within the access* conformer of AdeB-Et-III, an Et ligand is seen to occupy the entrance drug-binding site. Residues Q575, E654, M656, V658, M706, F669, W568, T605, E710, and I821 are engaged in the binding (Fig. 4). Like the structures of AdeB-Et-I and AdeB-Et-II, no Et ligand is found to bind in the extrusion protomer of AdeB.

**Computational simulation of the AdeB multidrug efflux pump.** To understand the molecular mechanism of drug transport via the AdeB pump, we performed molecular dynamics simulations based on the cryo-EM structures of the AdeB pump both in the absence (an extrusion protomer of the AdeB-Et-I structure) and presence (the binding protomer of the AdeB-Et-I structure) of Et ligands. One-microsecond production MD simulations were conducted for each protomer (Fig. S7). It appears that the conformations of the flexible loop (F-loop; residues 661 to 670), which connects the entrance and proximal sites of the periplasmic cleft, and the G-loop (residues 609 to 618) are directly related to the opening and closing of the periplasmic cleft. In the extrusion state, the periplasmic cleft is closed. It is observed that both the F- and G-loops contribute to block the periplasmic cleft and occlude the entrance and the proximal sites. In contrast, in the binding state, the F- and G-loops are positioned so that these binding sites open up and are made available for the ligands. We measured the minimum distances between residues F612 of the G-loop and T668 of the F-loop as a function of time in two different MD simulations, utilizing the structures of the extrusion protomer of AdeB-I and binding protomer of AdeB-Et-I. The simulations indicate that the minimum distances between these two residues are between 3 and 4 Å for the extrusion protomer, whereas these distances are between 4 and 15 Å in the binding protomer (Fig. S7). It appears that the conformation of the extrusion state is stabilized by hydrophobic interactions between residues T668, F669, and F612.

We then calculated the root mean square deviation (RMSD) of residues F612 and W610, located at the G-loop, as a function of time for the binding protomer. We observed that these two residues have very large RMSD values compared with the nearby residues F569 and W568, suggesting that F612 and W610 are highly flexible and very dynamic in nature (Fig. S7). It appears that the aromatic sidechains of these residues act as a “broom” to shuttle the bound ligand molecule out of the pump. This observation is indeed in good agreement with molecular dynamics simulations that suggest the AcrB F617 residue (corresponding to F612 of AdeB) is important for drug transport (32).

Interestingly, principal component analysis (PCA) based on the AdeB binding and extrusion protomers of the AdeB-Et-I structure indicates that the first eigenvector, which depicts the most important motion extracted from the MD simulation trajectory, represents the motions of the F-loop, G-loop, and another flexible loop (residues 131 to 139), all part of the distal drug-binding site, in addition to the relative movements of secondary structural elements making up the left side (residues 693 to 709 and 819 to 833 of PC2) and right side (residues 624 to 650 of PC1) of the periplasmic cleft. This result is in good agreement with our cryo-EM structures, depicting that the major conformational changes are the flexible loops inside the periplasmic cleft beside the opening and closing of the cleft between subdomains PC1 and PC2 (Fig. 5). These data strongly suggest that there are several coordinated motions within the entrance,
proximal, and distal drug-binding sites to help shuttle the bound drug molecule traveling through the channel formed by the AdeB protomer for drug export.

To further elucidate the mechanism of substrate transport, we performed target MD simulations using the NAMD program. We observed that the Et ligand indeed follows the path of the binding and extrusion channels to shuttle along the AdeB pump (Fig. 5). Based on the target MD calculations, Et first enters the AdeB pump via the entrance binding site, which includes residues M656 and W706. It then passes through the G-loop, reaches the hydrophobic patch binding site, and eventually leaves this membrane protein through the exit site formed by Q125 and Y749 (Fig. S8).

**DISCUSSION**

We have defined cryo-EM structures of the AdeB multidrug efflux pump in the presence of Et. These structural data allow us to observe new conformational states that have not been identified before for the RND efflux pumps. It appears that the transmembrane region of trimeric AdeB can be associated to form a trimer assembly or dissociated into dimer plus monomer and monomer plus monomer plus monomer configurations. The motion that governs the association and dissociation can be interpreted as a simple rigid-body rotation that allows the transmembrane regions of the AdeB protomers to tilt away from each other. The hinge of this long-distance conformational change is located at the periplasmic docking domain of the AdeB trimer, where the intersubdomains DN and DC are responsible for tethering the trimeric assembly of this pump. We postulate that this rigid-body rotational motion can trigger a conformational change of the AdeA membrane fusion protein. Similar to the assembly characteristics of the membrane fusion proteins CusA and AcrA seen in the CusAB (30) and AcrAB-TolC (29) complexes, AdeA is presumed to assemble as a hexameric channel to interact with the trimeric AdeB pump. The rigid-body rotational motion of AdeB may be responsible for controlling the opening and closing of the AdeA hexameric channel to facilitate drug extrusion. Thus far, there is no known evidence that AdeB can interact with membrane fusion proteins other than AdeA to function. However, it has been documented that the *Pseudomonas aeruginosa* MexB multidrug efflux pump can form a functional complex with the *E. coli* AcrA membrane fusion protein (37). The
multiple states of AdeB observed in the cryo-EM structures of AdeB may facilitate the interaction between AdeB and other membrane fusion proteins. The possibility that AdeB can associate with other membrane fusion proteins awaits further investigation.

Surprisingly, we only observed the trimer configuration at the transmembrane domain of the Et-bound AdeB structures. This indicates that the presence of substrate stabilizes the trimer assembly. One interpretation is that the conformation of the trimer state may be more compatible with AdeA binding, which in turn facilitates the extrusion of substrates out of bacterial cells.

The cryo-EM structures of AdeB-Et indicate that this pump also forms an asymmetric trimer. Surprisingly, in the AdeB-Et-I structure, the periplasmic cleft of one of the AdeB protomers is open, presenting the conformation of the binding state. However, the other two AdeB protomers are more or less identical in conformation, representing the extrusion transient state with the periplasmic clefts closed. These structural features are distinct from the typical conformation of the HAE-RND asymmetric trimeric pumps, including AcrB (34) and MtrD (36), where the three protomers display the binding, access, and extrusion forms with two periplasmic clefts open and one cleft closed.

Surprisingly, the structure of AdeB-Et-I also indicates that a single protomer of AdeB can simultaneously accommodate three bound Et molecules. These three Et ligands are bound at the entrance, distal, and hydrophobic patch drug-binding sites within this binding protomer, suggesting that the plasticity and flexibility of the pump accommodate the simultaneous binding of a number of ligands in a single AdeB protomer. It appears that the Et molecules line the path for drug extrusion, providing us with important information regarding the mechanism of drug export. It is obvious that a drug molecule enters the cleft of the AdeB binding protomer via the periplasmic entrance drug-binding site. The drug molecule will then pass through the proximal drug-binding site, traverse the G-loop, and reach the distal drug-binding site. Notably, the subsequent step is that the bound drug will arrive at the hydrophobic patch binding site, where this site is mostly hydrophobic in nature and mainly composed of aromatic residues, including F178, F277, and W610. Based on the structural information, it is likely that the drug molecule is needed to pass through the hydrophobic patch binding site before being evacuated from the AdeB pump.

Interestingly, the asymmetric trimeric structure of AdeB-Et-II resembles the conformation of the CmeB trimer (35), where the three protomers display resting, extrusion, and binding states, respectively. Again, we found that the binding protomer can accommodate multiple Et ligands simultaneously.

Unexpectedly, in the AdeB-Et-III complex, both the access* and binding protomers were occupied by Et ligands. This observation highlights a phenomenon that individual protomers within the AdeB trimer are capable of independently binding and exporting substrates, as indicated in the case of the C. jejuni CmeB multidrug efflux pump (35). Based on the X-ray structures of ligand-bound RND pumps, including those for AcrB (31, 38) and CusA (39, 40), it is possible that individual protomers of these trimeric pumps can bind substrates simultaneously.

Previously, a single-molecule fluorescence resonance energy transfer (FRET) imaging approach was used to study the functional transport dynamics of the C. jejuni CmeB trimeric efflux pump (35). It was observed that each CmeB protomer went through at least four different transient conformations within the transport cycle, and each CmeB protomer within the trimer was able to function independently. In the current work, we observe various conformational states, including the resting, access*, binding, and extrusion forms of the AdeB trimer, using the cryo-EM approach. Our findings also lead us to propose a model for the AdeB transport mechanism (Fig. 6). These experimental data are indeed in good agreement with the single-molecule FRET study of the CmeB pump (35) where each protomer goes through several transient states to open and close the periplasmic cleft accordingly to advance the transport cycle.
MATERIALS AND METHODS

Expression and purification of AdeB. The procedures for cloning, expression, and purification of the A. baumannii (AB0057) AdeB multidrug efflux pump were identical to what was described previously (41). The purified AdeB membrane protein was concentrated to 10 mg/ml in a buffer containing 20 mM Na-HEPES (pH 7.5) and 0.05% (wt/vol) n-dodecyl-β-D-maltoside (DDM).

Fluorescence polarization assay. The protocols of using fluorescence polarization to quantify $K_D$s of Et and R6G with AdeB were the same as those described for the AcrB multidrug efflux pump (26). The titration experiments were repeated four times to obtain the average $K_D$ value. Curve fitting was accomplished using Origin (OriginLab Corporation, Northampton, MA).

Ethidium bromide uptake. Cells from frozen stocks were inoculated into LB medium containing appropriate antibiotics and incubated for 16 h at 37°C. Cells were then subcultured into 30 ml of fresh LB medium and grown at 37°C to an optical density at 600 nm (OD600) of 0.3. The cells then were induced with 1% arabinose for both AbD3-pAdeABC and AbD3-Pore(pAdeABC) cells. Cells were grown until the OD600 was 1.0. Cells were collected by centrifugation at 3,266 g for 30 min at room temperature, and the pellet was washed in 25 ml of 50 mM HEPES-KOH buffer (pH 7.0) containing 1 mM MgSO4 and 0.4 mM glucose (HMG buffer) and pelleted at 3,266 g at room temperature. The pellet was resuspended in HMG buffer, adjusted to an OD 600 of 1.0, and kept at room temperature during the experiment.

An uptake assay was performed in a temperature-controlled multimode microplate reader (Tecan Spark 10M) equipped with a sample injector in fluorescence mode. The fluorescence of Et was monitored at an excitation wavelength of 480 nm and emission wavelength of 610 nm at a gain of 75 for 10 min, as described earlier (42). All measurements were done in duplicates and repeated at least three times.

Nanodisc preparation. To assemble AdeB into nanodiscs, a mixture containing 20 μM AdeB, 45 μM MSP (1E3D1), and 930 μM E. coli total extract lipid was incubated for 15 min at room temperature, and then 0.8 mg/ml prewashed Bio-beads (Bio-Rad) was added. The resultant mixture was incubated for 1 h on ice, followed by overnight incubation at 4°C. The protein-nanodisc solution was filtered through 0.22-μm nitrocellulose filter tubes to remove the Bio-beads. To separate free nanodiscs from AdeB-loaded nanodiscs, the filtered protein-nanodisc solution was purified using a Superose 6 column (GE Healthcare) equilibrated with 20 mM Tris-HCl, pH 7.0, and 100 mM NaCl. Fractions corresponding to the size of the trimeric AdeB-nanodisc complex were collected for cryo-EM sample preparation.

Electron microscopy sample preparation. A 2 μM AdeB-nanodisc sample was incubated with 20 μM Et for 2 h to form the AdeB-Et complex. The sample was then applied to lysine-coated graphene-oxide grids (Quantifoil Cu R1.2/1.3, 300 mesh) prepared in-house, blotted for 3 s, and then plunge-frozen in liquid ethane using a Vitrobot (Thermo Fisher). The grids were then transferred into cartridges. The images were recorded at −1 to −20 μm defocus on a Titan Krios equipped with a K3 summit direct electron detector (Gatan) with counting mode at nominal ×81,000 magnification, corresponding to a sampling interval of 1.08 Å/pixel (superresolution, 0.54 Å/pixel). Each micrograph was exposed for 2.6 s.
with 18.02 e−/Å²/physical pixel dose rate (total specimen dose, 40 e−/Å²), and 40 frames were captured per specimen area using Latitude.

Data collection and processing. The superresolution image stack was aligned, and contrast transfer function (CTF) was estimated using cryoSPARC (43). After manual inspection and sorting to discard poor images, 150 micrographs were picked via blob picker, and particles were classified to generate templates for automated template picking. Initially, 2,188,223 particles were selected after autopicking in cryoSPARC (43). Several iterative rounds of 2D classifications were performed to remove false picks and classes with unclear features, ice contamination, or carbon. The resulting 982,491 particles were further cleaned using ab initio and heterogeneous three-dimensional (3D) classification. Particles were extracted to full resolution. A single round of nonuniform refinement followed by local refinement with nonuniform sampling resulted in a consensus structure (see Fig. S2 in the supplemental material).

The consensus structure was then analyzed using 3D variability analysis (3DVA) in cryoSPARC (43). All 3DVA jobs were performed using four modes with a 5-Å filtered resolution. Initially, 3DVA was performed on the full AdeB trimeric protein, resulting in clear opening and closing states of the periplasmic cleft. To separate different conformations of these particles, the periplasmic domain of the AdeB trimer was masked and analyzed using 3DVA with identical settings. The results were clustered and separated into two classes based on the state of the periplasmic clefts and taken for further processing.

The trimeric AdeB particles with three closed periplasmic clefts were subjected to another round of 3DVA by masking the full trimeric protein. The results showed three distinct conformations at the transmembrane region of the pump. Particles were separated and cleaned using one more round of 3DVA. The resulting three distinct structures (AdeB-I, AdeB-II, and AdeB-III) were then refined using nonuniform refinement followed by local refinement with nonuniform sampling, resulting in global resolution maps of 3.64 Å for AdeB-I, 3.21 Å for AdeB-II, and 3.42 Å for AdeB-III based on the gold standard Fourier shell correlation (GS-FSC; 0.143). These maps were then processed using density modification (44) implemented in PHENIX (45), further improving the resolutions to 3.59 Å, 3.13 Å, and 3.27 Å for AdeB-I, AdeB-II, and AdeB-III, respectively (Fig. S2).

Model building and refinement. Model buildings of AdeB-I, AdeB-II, AdeB-III, AdeB-Et-I, AdeB-Et-II, and AdeB-Et-III were based on the 3.59-Å, 3.13-Å, 3.27-Å, 2.96-Å, 3.53-Å, and 3.21-Å cryo-EM maps, respectively. The structure of AdeB (PDB entry 6OWS) (41) was fit into the density maps as a starting model using Chimera (46). The subsequent model rebuilding was performed using Coot (47). Structural refinements were performed using the phenix.real_space_refine program (48) from the PHENIX suite (45). The final atomic model was evaluated using MolProbity (49). The statistics associated with data collection, 3D reconstruction, and model refinement are included in Table S1.

MD simulations. The protonation states of the titratable residues of the AdeB pump were determined using the H++ server (http://biophysics.cs.vt.edu/). We used the binding protomer (AdeB [Et]) and one of the extrusion protomers (AdeB [apo]) of the cryo-EM structure of the AdeB-Et-I complex as the template. These two structures were separately immersed in an explicit lipid bilayer consisting of POPC and POPE with a molecular ratio of 1:1 and a water box with dimensions of 152.7 Å by 152.7 Å by 163.6 Å using the CHARMM-GUI Membrane Builder webserver (http://www.charmm-gui.org/?doc=input/membrane). We then added 150 mM NaCl and extra neutralizing counter ions for the simulations. The total numbers of atoms were 281,283 and 278,953 for the AdeB (apo) and AdeB (Et) systems, respectively. The Antechamber module of AmberTools was employed to generate parameters for Et by using the general AMBER force field (GAFF) (50, 51). The partial charges of Et were calculated using ab initio quantum chemistry at the HF/6-31G* level (GAUSSIAN 16 program) (Gaussian Inc., Wallingford, CT). The RESP charge-fitting scheme was used to calculate partial charges on the atoms (52). The PMEMD.CUDA program implemented in AMBER18 (UCSF) was used to conduct MD simulations. The simulations were performed with periodic boundary conditions to produce isothermal-isobaric ensembles. Long-range electrostatics were calculated using the particle mesh Ewald (PME) method (53) with a 10-Å cutoff. Prior to the calculations, energy minimization of these systems was carried out. Subsequently, the systems were heated from 0 K to 300 K using Langevin dynamics with a collision frequency of 1 ps⁻¹. During heating, the AdeB protomer was position restrained using an initial constant force of 500 kcal/mol/Å² and weakened to 10 kcal/mol/Å² to allow for the movement of lipid and water molecules. The systems then went through 5-ns equilibrium MD simulations. Finally, 1-µs production MD simulations were conducted. During simulations, the coordinates were saved every 100 ps for analysis. GROMCAS analysis tools were used for the MD simulation trajectory analysis (54).

TMD simulation (TMD) was performed using the NAMD program (55) with the AMBER force field parameters described above. In the simulations, we selected the heavy atoms of the Et ligand at the entrance binding site to be guided toward the target position at the hydrophobic patch-binding site by the application of steering forces. The root mean square (RMS) distance between the current coordinates and the target structure was calculated at each time step. The force on each selected atom was given by a gradient of potential as a function of the RMS values. The system went through energy minimization, heating, and 15-ns equilibrium MD simulations. TMD simulation then was performed for...
5 ns based on the MD equilibrated coordinates. A value of 500 kcal/mol/Å² was used as an elastic constant for TMD forces during the simulations.

**Data availability.** Atomic coordinates and density maps have been deposited under accession codes 7KGF (PDB) and EMD-22866 (EMDB) for AdeB-I, 7KGE (PDB) and EMD-22867 (EMDB) for AdeB-II, 7KGF (PDB) and EMD-22868 (EMDB) for AdeB-III, 7KGG (PDB) and EMD-22869 (EMDB) for AdeB-Et-I, 7KGH (PDB) and EMD-22870 (EMDB) for AdeB-Et-II, and 7KGI (PDB) and EMD-22871 (EMDB) for AdeB-Et-III.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1**, PDF file, 0.4 MB.  
**FIG S2**, PDF file, 0.1 MB.  
**FIG S3**, PDF file, 0.2 MB.  
**FIG S4**, PDF file, 0.9 MB.  
**FIG S5**, PDF file, 0.2 MB.  
**FIG S6**, PDF file, 0.2 MB.  
**FIG S7**, PDF file, 1.5 MB.  
**FIG S8**, PDF file, 1.3 MB.  
**TABLE S1**, PDF file, 0.03 MB.  
**TABLE S2**, PDF file, 0.04 MB.

**ACKNOWLEDGMENTS**

We thank Ann E. Jerse and Philip A. Klenotic for proofreading the manuscript.

This work was supported by NIH grants R01AI145069 (E.W.Y.) and R01AI132836 (H.I.Z.). This research was supported in part by the National Cancer Institute Cryo-EM Facility at the Frederick National Laboratory for Cancer Research under contract HSSN261200800001E.

**REFERENCES**

1. Gordon NC, Wareham DW. 2010. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 35:219–226. https://doi.org/10.1016/j.ijantimicag.2009.10.024.

2. Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC, Lee SH. 2017. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 7:555. https://doi.org/10.3389/fcimb.2017.00555.

3. Kim YJ, Kim SI, Kim YR, Hong KW, Wie SH, Park YJ, Jeong H, Kang MW. 2012. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect 140:137–145. https://doi.org/10.1017/S095026881000744.

4. CDC. 2019. Antibiotic resistance threats in the United States. CDC, Atlanta, GA.

5. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. https://doi.org/10.1016/S1473-3099(17)30753-3.

6. Ökokonou M, Sarro S, Papagiannis CC, Georgiadis S, Mantzarlis K, Zakythinos E, Dalekos GN, Petinati E. 2015. Rapid dissemination of colistin resistance and carbapenem resistant Acinetobacter baumannii in central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis 15:355. https://doi.org/10.1186/s12879-015-1297-x.

7. Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O’Hara JA, Doi Y, Clancy CJ, Shields RK. 2014. In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother 58:1195–1199. https://doi.org/10.1128/AAC.01779-13.

8. Navon-Venezia S, Leavitt A, Carmeli Y. 2007. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59:772–774. https://doi.org/10.1093/jac/dkm018.

9. Deng M, Zhu MH, Li JJ, Bi SL, Sheng ZK, Hu FS, Zhang JJ, Chen W, Xue XW, Sheng JF, Li LJ. 2014. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother 58:297–303. https://doi.org/10.1128/AAC.01727-13.

10. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582. https://doi.org/10.1128/CMR.00058-07.

11. Darnieri-Pioli L, Magnet S, Breumont S, Lambert T, Courvalin P. 2008. AdeJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 52:557–562. https://doi.org/10.1128/AAC.00732-07.

12. Piddock LJ. 2006. Multidrug-resistance efflux pumps—not just for resistance. Nat Rev Microbiol 4:629–636. https://doi.org/10.1038/nrmicro1464.

13. Magnet S, Courvalin P, Lambert T. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM454. Antimicrob Agents Chemother 45:3375–3380. https://doi.org/10.1128/AAC.45.12.3375-3380.2001.

14. Coyne S, Rosenfeld N, Lambert T, Courvalin P, Perichon B. 2010. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 54:4389–4393. https://doi.org/10.1128/AAC.00155-10.

15. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. 2004. Selection of topo-isomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 54:821–823. https://doi.org/10.1093/jac/dkh427.

16. Ruvin A, Keeney D, Bradford PA. 2007. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 59:1001–1004. https://doi.org/10.1093/jac/dkm058.

17. Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, Huse HK, Zurawski DV, Brittmacher MJ, Manoli C. 2015. Resources for genetic and genomic analysis of emerging pathogen Acinetobacter baumannii. J Bacteriol 197:2027–2035. https://doi.org/10.1128/JB.00131-15.

18. Peleg AY, Adams J, Paterson DL. 2007. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 51:2065–2070. https://doi.org/10.1128/AAC.01198-06.

19. Lari AR, Ardebili A, Hashemi A. 2018. AdeR-AdeS mutations and overexpression of adeR adeS in Acinetobacter baumannii. Front Cell Infect Microbiol 8:303. https://doi.org/10.3389/fcimb.2017.00303.

20. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. 2004. Selection of topo-isomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 54:821–823. https://doi.org/10.1093/jac/dkh427.
Cryo-EM Structures of AdeB

of the adeB gene in clinical isolates of tigecycline-non-susceptible Acinetobacter baumannii without insertion mutations in adeR5. Antimicrob Agents Chemother 54:4934–4938. https://doi.org/10.1128/AAC.00414-10.

21. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. 2004. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeR5 two-component system. Antimicrob Agents Chemother 48:3298–3304. https://doi.org/10.1128/AAC.48.9.3298-3304.2004.

22. Wieczorek P, Sacha P, Czaban S, Hauschild T, Ojdana D, Kowalczuk O, Milewski R, Poniatowski B, Niklinski J, Tryniowska E. 2013. Distribution of AdeABC efflux system genes in genotypically diverse strains of clinical Acinetobacter baumannii. Diagn Microbiol Infect Dis 77:106–109. https://doi.org/10.1016/j.diagmicrobio.2013.06.017.

23. Ho CM, Beck JR, Lai M, Cui YX, Goldberg DE, Egea PF, Zhou ZH. 2018. Malaria parasite translocon structure and mechanism of effector export. Nature 561:70–75. https://doi.org/10.1038/s41586-018-0469-4.

24. Morgan CE, Huang W, Rudin SD, Taylor DJ, Kirby JE, Bonomo RA, Yu EW. 2020. Cryo-electron microscopy structure of the Acinetobacter baumannii 705 ribosome and implications for new antibiotic development. mBio 11:12. https://doi.org/10.1128/mBio.03179-19.

25. Su CC, Morgan CE, Bolla JR, Robinson CV, Yu EW. 2021. A “build and retrieve” methodology to simultaneously solve cryo-EM structures of membrane proteins. Nat Methods 18:69–75. https://doi.org/10.1038/s41592-020-0921-2.

26. Su CC, Nikaido H, Yu EW. 2007. Ligand-transporter interaction in the AcrB multidrug efflux pump determined by fluorescence polarization assay. FEBS Lett 581:4972–4976. https://doi.org/10.1016/j.febslet.2007.09.035.

27. Sugawara E, Nikaido H. 2014. Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumannii compared with those of the AcrAB-ToLC system of Escherichia coli. Antimicrob Agents Chemother 58:7250–7257. https://doi.org/10.1128/AAC.03728-14.

28. Leus IV, Weeks JW, Bonifay V, Smith L, Richardson S, Zgurskaya HI. 2018. Subunit structure and specificity of RND efflux pumps of Acinetobacter baumannii. J Bacteriol 200:e00094-18. https://doi.org/10.1128/JB.00094-18.

29. Du DJ, Wang Z, James NR, Voss JE, Klimont E, Ohene-Agyei T, Venter H, Chiu W, Luisi BF. 2014. Structure of the AcrAB-TolC multidrug efflux complex of Escherichia coli. Nature 470:558–562. https://doi.org/10.1038/nature09743.

30. Yu EW, McDermott G, Zgurskaya HI, Nikaido H, Koshland DE, Jr. 2003. Structural basis of multiple drug-binding capability of the AcrB multidrug efflux pump. Science 300:976–980. https://doi.org/10.1126/science.1083137.

31. Yu EW, McDermott G, Zgurskaya HI, Nikaido H, Koshland DE, Jr. 2003. Crystal structure of the CusBA heavy-metal efflux complex of Escherichia coli. Nature 470:558–562. https://doi.org/10.1038/nature09743.

32. Vargiu AV, Nikaido H. 2012. Multidrug binding properties of the AcrB efflux pump. Nature 458:345–349. https://doi.org/10.1038/nature07670.

33. Su CC, Yin L, Kumar N, Dai L, Radhakrishnan A, Bolla JR, Lei HT, Chou TH, Delmar JA, Rajashankar KR, Zhang Q, Shin YK, Yu EW. 2017. Structures and transport dynamics of a Campylobacter jejuni multidrug efflux pump. Nat Commun 8:171. https://doi.org/10.1038/ncomms1739.

34. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. 2006. Charged amino acids (R83, E567, D617, E625, R669, and K678) of CusA are required for metal ion transport in the Cus efflux system. J Mol Biol 422:429–441. https://doi.org/10.1016/j.jmb.2012.05.038.

35. Su CC, Morgan CE, Kambakam S, Rajavel M, Scott H, Huang W, Emerson CC, Taylor DJ, Stewart PL, Bonomo RA, Yu EW. 2019. Cryo-electron microscopy structure of an Acinetobacter baumannii multidrug efflux pump. mBio 10.e01295-19. https://doi.org/10.1128/mBio.01295-19.

36. Saha P, Sridar S, Krishnamoorthy G, Zgurskaya HI, Rybenkov VV. 2020. Drug permeation against efflux by two transporters. ACS Infect Dis 6:747–758. https://doi.org/10.1021/acsinfecdis.9b00510.

37. Krishnamoorthy G, Tikhonova EB, Zgurskaya HI. 2008. Fitting periplasmic membrane fusion proteins to inner membrane transporters: mutations that enable Escherichia coli AcrA to function with Pseudomonas aeruginosa MexD. J Bacteriol 190:691–698. https://doi.org/10.1128/JB.01276-07.

38. Yu EW, Aires JR, McDermott G, Nikaido H. 2005. A peripolar drug-binding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J Bacteriol 187:6804–6815. https://doi.org/10.1128/JB.187.19.6804-6815.2005.

39. Long F, Su CC, Zimmermann MT, Boyken SE, Rajashankar KR, Jernigan RL, Yu EW. 2010. Crystal structures of the CusA efflux pump suggest methionine-nine-mediated metal transport. Nature 467:484–488. https://doi.org/10.1038/nature09395.

40. Su CC, Long F, Li HT, Bolla JR, Do SV, Rajashankar KR, Yu EW. 2012. Charged amino acids (R83, E567, D617, E625, R669, and K678) of CusA are required for metal ion transport in the Cus efflux system. J Mol Biol 422:429–441. https://doi.org/10.1016/j.jmb.2012.05.038.

41. Saha P, Sridar S, Krishnamoorthy G, Zgurskaya HI, Rybenkov VV. 2020. Drug permeation against efflux by two transporters. ACS Infect Dis 6:747–758. https://doi.org/10.1021/acsinfecdis.9b00510.

42. Saha P, Sridar S, Krishnamoorthy G, Zgurskaya HI, Rybenkov VV. 2020. Drug permeation against efflux by two transporters. ACS Infect Dis 6:747–758. https://doi.org/10.1021/acsinfecdis.9b00510.